Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
NCT ID: NCT03844360
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
1500 participants
INTERVENTIONAL
2016-01-31
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
NCT03643276
Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
NCT06387121
Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies
NCT02011022
DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
NCT03356080
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
NCT06233526
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antineoplastic Drugs and Anti-infective Drugs
Bortezomib;eltrombopag;imatinib;dasatinib, pegaspargase and anti-infective drugs administered at standard dose for children with hematological neoplasms.
Bortezomib
bortezomib was administered follow the doctor's advice.
Eltrombopag
eltrombopag was administered follow the doctor's advice.
Imatinib
imatinib was administered follow the doctor's advice.
dasatinib
dasatinib was administered follow the doctor's advice.
Pegaspargase
pegaspargase was administered follow the doctor's advice.
Anti-Infective Drugs
anti-infective drugs was administered follow the doctor's advice.
PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
pegaspargase was administered follow the doctor's advice.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bortezomib
bortezomib was administered follow the doctor's advice.
Eltrombopag
eltrombopag was administered follow the doctor's advice.
Imatinib
imatinib was administered follow the doctor's advice.
dasatinib
dasatinib was administered follow the doctor's advice.
Pegaspargase
pegaspargase was administered follow the doctor's advice.
Anti-Infective Drugs
anti-infective drugs was administered follow the doctor's advice.
PEGylated Recombinant Human Granulocyte Colony-Stimulating Factor
pegaspargase was administered follow the doctor's advice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Antineoplastic drugs or anti-infective drugs used as part of regular treatment
Exclusion Criteria
* patients with other factors that researcher considers unsuitable for inclusion.
1 Day
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Wei Zhao
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Zhao
Professor; Head of department of clinical pharmacy and pharmacology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Zhao, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Shandong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Pediatrics, the Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Tanjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Zhang W, Chang LX, Zhao BB, Zheng Y, Shan DD, Tang BH, Yang F, Zhou Y, Hao GX, Zhang YH, van den Anker J, Zhu XF, Zhang L, Zhao W. Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia. J Clin Pharmacol. 2024 Aug;64(8):932-943. doi: 10.1002/jcph.2430. Epub 2024 Mar 18.
Yang F, Zhang L, Zhao BB, Zhang JL, Liu XT, Li X, Tang BH, Zhou Y, Yang XM, van den Anker J, Zhu XF, Zhao W. Population Pharmacokinetics and Safety of Dasatinib in Chinese Children with Core-Binding Factor Acute Myeloid Leukemia. Clin Pharmacokinet. 2022 Jan;61(1):71-81. doi: 10.1007/s40262-021-01054-6. Epub 2021 Jul 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Antineoplastic Drugs001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.